Prevalence of hepatitis and HIV infections and vaccination rates in patients entering the heroin-assisted treatment in Switzerland between 1994 and 2002

Eur J Epidemiol. 2006;21(7):545-9. doi: 10.1007/s10654-006-9023-z. Epub 2006 Jul 21.

Abstract

Background: Hepatitis C virus (HCV) remains very prevalent in injection drug users (IDUs). In spite of recommended vaccinations against hepatitis A virus (HAV) and hepatitis B virus (HBV), many IDUs remain susceptible to HAV and HBV.

Study population and methods: Patients entering heroin-assisted treatment between 2000 and 2002 (N = 210) were compared for infectious disease status with patients entering this treatment in 1998 (N = 243) and between 1994 and 1996 (N = 1035). Infection status was determined with the aid of questionnaires and blood tests for antibodies against HAV, HBV core antigen, HCV and HIV.

Results: In the cohort 2000-2002 78.3% of the patients were HCV positive, 53.3% were HBV positive, 41.2% were HAV positive and 12.6% were HIV positive. In comparison to the cohorts entering the heroin- assisted treatment at an earlier time, there was a significant reduction of HBV and HAV infections, but not of HCV and HIV infections. 15.6% of the patients entering between 2000 and 2002 were vaccinated against HBV and 10.3% against HAV. 31.1% of patients at entrance were susceptible for HBV and 48.5% for HAV. In comparison to patients entering treatment in 1998 there was no significant increase in patients who were vaccinated against HBV.

Conclusions: This data illustrates the need for improving HCV prevention and more consequent vaccination against HBV and HAV in IDUs.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Female
  • HIV Infections / epidemiology*
  • Hepatitis A / epidemiology*
  • Hepatitis A / prevention & control
  • Hepatitis A Antibodies / analysis
  • Hepatitis B / epidemiology*
  • Hepatitis B / prevention & control
  • Hepatitis B Antibodies / analysis
  • Hepatitis C / epidemiology*
  • Hepatitis C / prevention & control
  • Hepatitis C Antibodies / analysis
  • Heroin Dependence* / complications
  • Heroin Dependence* / therapy
  • Humans
  • Longitudinal Studies
  • Male
  • Prevalence
  • Substance Abuse Treatment Centers / statistics & numerical data*
  • Substance Abuse, Intravenous / virology
  • Surveys and Questionnaires
  • Switzerland / epidemiology
  • Vaccination / statistics & numerical data*
  • Viral Hepatitis Vaccines / therapeutic use*

Substances

  • Hepatitis A Antibodies
  • Hepatitis B Antibodies
  • Hepatitis C Antibodies
  • Viral Hepatitis Vaccines